A system and method for adjusting or selecting the treatment parameters for hifu signals to treat a target treatment site, and/or to aid in visualizing the likely degree and location of hifu effects on patient tissue. The system transmits one or more test signals into patient tissue and receives signals created in response to the test signals. The signals are analyzed to determine a response curve of how a characteristic of the signal varies with the one or more test signals. The response curve of the detected signals is used to select a treatment parameter.
|
40. A method of adjusting a focal location of an ultrasound transducer, comprising:
transmitting an ultrasound signal into tissue at an intended focal location with a first transducer;
receiving echo signals from the tissue with a second transducer;
determining the energy of the received echo signals in a first frequency range and a second frequency range;
comparing the energy of the received echo signals in the first frequency range to the energy of the received echo signals in the second frequency range by computing a ratio of the energy of the received echo signals in the first frequency range to the energy of the received echo signals in the second frequency range, wherein the ratio of the energy of the received echo signals relates how energy in the ultrasound signal at a frequency in the second frequency range transfers to one or more harmonic frequencies in the first frequency range; and
using the computed ratio to adjust the focal location of the first transducer.
41. A high intensity focused ultrasound (hifu) system to treat tissue at a target treatment site, comprising:
an ultrasound transducer that is configured to deliver a test signal to a tissue site at an intended focal location;
a controller that is operates to adjust the intended focal location of the ultrasound transducer;
a receiver that is configured to receive echo signals at a number of spatial locations in the tissue site; and
a processor programmed to compare the energy of the received echo signals in a first frequency range to the energy of the received echo signals in a second frequency range for the spatial locations by computing a ratio of the energy of the received echo signals in the first frequency range to the energy of the received echo signals in the second frequency range, wherein the ratio of the energy of the received echo signals relates how energy in the test signal at a frequency in the second frequency range transfers to one or more harmonic frequencies in the first frequency range, and further use the computed ratio to adjust the focal location of the ultrasound transducer.
36. A method of adjusting a focal location of a hifu transducer, the method comprising:
transmitting two or more test signals at different power levels into tissue at an intended focal location, wherein two or more of the test signals are transmitted at a selected frequency;
receiving echo signals at a number of spatial locations in the tissue, wherein the echo signals result from transmission of the two or more test signals into the tissue;
determining one or more response curves for the tissue at each of the spatial locations that indicate how a signal characteristic of the echo signals changes with changes in the power level of the two or more test signals, wherein at least one of the response curves relates how energy in the test signals transfers from the selected frequency to one or more harmonics of the selected frequency with the different power levels of the test signals, and wherein the one or more response curves compare energy in the echo signals resulting from a test signal transmitted at a first power level to energy in the echo signals resulting from a test signal transmitted at a second power level by computing a ratio of the energy of the echo signals at the first power level to the energy of the echo signals at the second power level;
analyzing the one or more response curves to determine an estimate of an actual focal location; and
adjusting the intended focal location based on the estimate of the actual focal location.
1. A method of operating a high intensity focused ultrasound (hifu) system to treat a target treatment site, the method comprising:
transmitting two or more test signals into a tissue site, wherein two or more of the test signals are transmitted at different power levels at a fundamental frequency;
detecting signals from an area of the tissue site, wherein the detected signals result from transmission of the two or more test signals into the tissue site;
determining one or more response curves for the tissue site that indicate how a signal characteristic of the detected signals changes in response to the different power levels of the two or more test signals, wherein at least one of the response curves relates how energy in the test signals transfers from the fundamental frequency to one or more harmonics of the fundamental frequency with the different power levels of the test signals by comparing the energy of the detected signals at the fundamental frequency to the energy of the detected signals at the one or more harmonics using a computed ratio of the energy of the detected signals at the fundamental frequency to the energy of the detected signals at the one or more harmonics;
using at least one of the determined response curves to select a treatment parameter of hifu signals that will be used to treat the target treatment site; and
applying hifu signals with the selected treatment parameter to the target treatment site with the hifu system.
33. A system for applying hifu signals to a subject, the system comprising:
a hifu controller configured to produce electronic hifu driving signals having one or more adjustable characteristics that affect an energy of a delivered hifu signal;
a hifu transducer configured to receive the electronic hifu driving signals, produce acoustic hifu signals at a fundamental frequency, and apply the acoustic hifu signals to tissue of a subject;
a receiving transducer configured to detect echo signals from the tissue of the subject;
a processor configured to receive the detected echo signals and compare an energy of the echo signals in a first frequency range to an energy of the echo signals in a second frequency range at a number of locations in the tissue; and
a display for displaying an image of the tissue along with an image representative of the comparison at one or more locations in the tissue,
wherein the processor is configured to compare the energy of the echo signals in the first frequency range to the energy of the echo signals in the second frequency range by computing a ratio of the energy of the echo signals in the first frequency range to the energy of the echo signals in the second frequency range, wherein the ratio of the energy of the echo signals relates how energy in the hifu signals transfers from the fundamental frequency to one or more harmonics of the fundamental frequency, and
wherein the processor is configured to use the computed ratio of the energy of the echo signals to select a power level of the acoustic hifu signals which adjusts the energy delivered by the hifu signals in the tissue of the subject.
39. A high intensity focused ultrasound (hifu) system to treat tissue at a target treatment site, the system comprising:
an ultrasound transducer that is configured to deliver two or more test signals at a focal location, wherein the two or more test signals are transmitted at different power levels;
a controller that is operates to adjust the focal location of the ultrasound transducer;
a receiver that is configured to detect echo signals at a number of spatial locations, wherein the detected echo signals result from transmission of the two or more test signals into the spatial locations; and
a processor that is programmed to analyze the detected echo signals to determine one or more response curves that indicate how a signal characteristic of the detected echo signals changes in response to the two or more test signals transmitted at the different power levels into the spatial locations, wherein at least one of the response curves relates how energy in the test signals transfers from a selected frequency to one or more harmonics of the selected frequency with the different power levels of the test signals, and wherein the one or more response curves compare energy in the echo signals resulting from a test signal transmitted at a first power level to energy in the echo signals resulting from a test signal transmitted at a second power level by computing a ratio of the energy in the echo signals at the first power level to the energy of the echo signals at the second power level, and
wherein the processor is programmed to cause the controller to adjust the focal location of the ultrasound transducer based on at least one of the determined response curves.
14. A high intensity focused ultrasound (hifu) system to treat tissue at a target treatment site, the system comprising:
an ultrasound transducer that is configured to deliver two or more test signals to a tissue site, wherein at least two of the test signals are transmitted at different power levels at a fundamental frequency;
a controller that is configured to control the ultrasound transducer to deliver the two or more test signals to the tissue site;
a receiver that is configured to detect signals from the tissue site, wherein the detected signals result from transmission of the two or more test signals into the tissue site;
a processor programmed to analyze the detected signals to determine one or more response curves for the tissue site that indicate how a signal characteristic of the detected signals changes in response to the different power levels of the two or more test signals, wherein at least one of the response curves relates how energy in the test signals transfers from the fundamental frequency to one or more harmonics of the fundamental frequency with the different power levels of the test signals by comparing the energy of the detected signals at the fundamental frequency to the energy of the detected signals at the one or more harmonics using a computed ratio of the energy of the detected signals at the fundamental frequency to the energy of the detected signals at the one or more harmonics,
wherein the ultrasound transducer is further configured, under control of the controller, to deliver hifu signals to the target treatment site with a selectable treatment parameter, and
wherein the processor is programmed to select the treatment parameter for the hifu signals to be used in treating the target treatment site based on at least one of the determined response curves.
2. The method of
3. The method of
4. The method of
5. The method of
6. The method of
7. The method of
8. The method of
9. The method of
10. The method of
11. The method of
12. The method of
13. The method of
15. The system of
16. The system of
17. The system of
18. The system of
19. The system of
20. The system of
21. The system of
22. The system of
23. The system of
24. The system of
28. The system of
29. The system of
30. The system of
31. The system of
32. The system of
34. The system of
35. The system of
37. The method of
38. The method of
42. The high intensity focused ultrasound (hifu) system of
43. The method of
determining a location of a maximum difference in the energy in the first and second frequency ranges as an estimate of an actual focal location; and
adjusting the intended focal location based on the estimate of the actual focal location.
|
This application is a continuation-in-part of U.S. patent application Ser. No. 12/187,318, filed Aug. 6, 2008, and also claims the benefit of U.S. Patent Application No. 61/180,187, filed May 21, 2009, both of which are expressly incorporated herein by reference.
As an alternative to more invasive types of surgical procedures, many physicians are employing the use of High Intensity Focused Ultrasound (HIFU) as a technique to therapeutically treat internal body tissues. With HIFU, an ultrasound signal of sufficient power (pressure and particle velocity) and time is focused on a target volume of tissue in order to change a state of the tissue by heating and/or by cavitation.
To be effective in treating tissue, the delivered energy of the HIFU signal must be sufficient to cause the desired physical effect. Additionally, the energy must not be so great or uncontrolled as to cause unintended collateral damage to healthy tissues surrounding the target volume. The non-homogenous nature of tissue(s) in the body creates variations in attenuation, propagation velocity, and acoustic impedance that modify the expected acoustic wave propagation and deposition of HIFU energy delivered to a target tissue volume when compared to homogeneous material. The technology disclosed herein is a method and apparatus for dynamically controlling and/or selecting parameters that affect the energy of a HIFU signal and/or the location where the energy is directed so that the desired physical effect in tissue is obtained and collateral damage to surrounding tissue is minimized.
As indicated above, the technology disclosed herein is a method and apparatus for selecting and/or controlling one or more treatment parameters such as the energy of a HIFU signal delivered by a transducer to a desired location in a patient. The one or more treatment parameters are selected or controlled based on an analysis of harmonic distortion or other changes in a detected signal characteristic that occur as a result of a high amplitude pressure waveform traveling through tissue.
To select a treatment parameter of a HIFU signal that will be used to treat a target tissue site, one or more test signals are delivered to the tissue. Each test signal is a continuous wave (CW) or pulsed mode ultrasound signal that is focused on a target volume in the patient. Signals created by the test signals are received and analyzed to determine a response curve of the tissue that indicates how a signal characteristic changes in response to the one or more test signals. Examples of detected signal characteristics include but are not limited to: energy, power, amplitude, frequency, energy at one or more frequencies or range of frequencies, duration, temperature change, dispersion or acoustic radiation force. The treatment parameter is selected or controlled based on the response curve(s).
In one embodiment, a response curve is compared to find a match against predefined response curves having treatment parameters associated therewith and the treatment parameter(s) of the closest matching response curve is selected.
In another embodiment, a treatment parameter is selected by analyzing a characteristic of the response curve, such as a saturation point or slope and the treatment parameter(s) associated with the characteristic is selected.
In yet another embodiment, a treatment parameter is selected by comparing the response curves to threshold values.
In one embodiment, the response curve is determined by comparing the energy of the received signals created from the test signals in one frequency range to the energy of the received signals in a second frequency range. This comparison is used to calculate K, which is the ratio of the energy in the two frequency ranges. In one embodiment, the energy in the harmonic content of the waveform is compared to the energy in the fundamental frequency. In another embodiment, the energy in a single harmonic, such as the second harmonic, is compared to the energy at the fundamental frequency. In yet another embodiment, the energy in one group of frequencies is compared to the energy in another group of frequencies, of which one may contain the fundamental frequency. In yet another embodiment, the phase difference for the harmonics can be used to calculate K.
The ratio K may be found for a multitude of spatial positions from the transducer. This may be accomplished through windowing of the received signals from the tissue at a specific time and calculating the Fourier transform. The response curve formed by the values of K as a function of spatial location may be compared to a baseline response curve, and the excitation signal may be adjusted to optimize the HIFU energy delivered to the intended target volume.
In one particular embodiment, the disclosed technology relates to a method and apparatus for selecting a power level for a high intensity focused ultrasound (HIFU) signal to be delivered by a HIFU transducer that operates by: transmitting a test signal having a fundamental frequency to a target volume; receiving ultrasound echoes from one or more positions; determining an energy of the received echoes in a first frequency range and an energy of the echo signals in a second frequency range; comparing the energy of the received echoes in the first frequency range and the energy of the echo signals in the second frequency range; and based on the comparison, adjusting one or more characteristics of the HIFU signal to adjust the energy of the HIFU signal delivered by the HIFU transducer.
In still a further embodiment, the method and apparatus operate such that the first frequency range does not include the fundamental frequency of the test signal and the second frequency range does include the fundamental frequency of the test signal.
In still a further embodiment, the method and apparatus operate such that the first frequency range includes one or more harmonics of the fundamental frequency of the test signal.
In still a further embodiment, the method and apparatus operate such that the energy of the received echoes in the first frequency range and the energy of the echoes in the second frequency range are compared by determining a ratio of an energy of the echoes in the first frequency range to an energy of the echoes in the second frequency range.
In yet another embodiment, the method and apparatus operate such that the delivered energy of the HIFU signal is adjusted by determining if the ratio at a selected position is less than a threshold, and if so, adjusting a characteristic of the HIFU signal to increase the delivered energy of the HIFU signal at the selected position.
In yet another embodiment, the method and apparatus operate so that the delivered energy of the HIFU signal is adjusted by determining if the ratio at a selected position is greater than a threshold, and if so, adjusting a characteristic of the HIFU signal to decrease the delivered energy of the HIFU signal at the selected position.
In yet another embodiment, the method and apparatus operate so that the energy of the echoes in the first frequency range and the energy of the echoes in the second frequency range are compared by determining a difference in phase between the echoes in the first frequency range and the second frequency range.
In yet another embodiment, the method and apparatus operate so that the adjustment of one or more characteristics of the HIFU signal is made based on the magnitude of the difference in phase.
In another embodiment, the response curve of the signal characteristic relates a dispersion of an echo signal to variations in test signal power. The dispersion may be detected as an amount of speckle shift toward the HIFU transducer. The one or more treatment parameters are controlled or selected based on the amount of speckle shift detected.
In another embodiment, the response curve of the signal characteristic relates how the energy contained in a received signal at one harmonic or at the fundamental frequency of the test signals varies in response to variations in test signal power.
In another embodiment, the response curve of the signal characteristic relates how a speckle shift due to heating within the tissue changes with changes in test signal power.
In one embodiment, a single test signal at each power level is used to measure the response of the signal characteristic. In another embodiment, two interrogations signals are used for each power level tested. The interrogation signals have the same overall power, but are 180 degrees out of phase. In this case, the signals received from tissue created by the two signals are added together to suppress the fundamental frequency and give a record of the harmonics generated within tissue.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
The foregoing aspects and many of the attendant advantages of the disclosed technology will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
Although the technology disclosed herein is described with respect to its currently preferred embodiments and the best mode known for practicing the technology, the description is not to be construed as limiting. The disclosure is directed to all new and non-obvious features and aspects of the disclosed embodiments either taken alone or in combination. As discussed above, the technology disclosed herein relates to techniques for adjusting or selecting one or more treatment parameters of a HIFU signal such as the energy of a HIFU signal and/or the location at which the energy is delivered. For the purposes of this application, the energy of a HIFU signal may be characterized by its power, pressure or other related characteristic. Other treatment parameters that can be controlled or selected include the treatment times of the HIFU signals, pulse repetition frequency, pulse duration of the HIFU signals or other parameters that effect the amount or rate at which energy is deposited at a tissue treatment site.
As will be described in further detail below, the one or more treatment parameters of the HIFU signals that are used to treat a tissue site are controlled or selected based on an analysis of how the signal characteristics of received signals vary in response to one or more test signals. In a currently preferred embodiment, the test signals are one or more HIFU signals. However, the test signals could be any type of ultrasound signal including non-focused or imaging ultrasound signals. The same transducer may be used to deliver both the therapeutic HIFU signals and the test signals or different ultrasound transducers could be used.
In one embodiment, to select the value of a treatment parameter, a number of test signals at different power levels are transmitted into the tissue. The test signals may be transmitted to the same tissue region as the target treatment site or the test signals may be transmitted into tissue into tissue that is nearby the target treatment site.
As the power level of the test signals increase, the transmitted test signals become increasingly non-linear in the tissue in the focal zone of the ultrasound transducer. The non-linearity creates a corresponding response curve of a signal characteristic that can be detected and used to select the appropriate treatment parameter. In one embodiment, the response curve is analyzed for a power level of a test signal that causes the detected signal characteristic to saturate. The saturation power level is used as a basis for selecting the treatment parameter.
The treatment parameter may be selected for each tissue site to be treated. Alternatively, the selected treatment parameter may be used to treat several different areas or cross-sections of the tissue site to be treated.
The energy of the echo signals as a function of frequency may be computed at different depths or spatial locations. In one case, the received echo signal is multiplied by a windowing function centered at a specific depth and the Fourier transform operator is applied. In the example shown in
The Fourier transform determines the energy that occurs in a number of frequency bins. Therefore, the energy in a particular frequency bin may be compared to the energy in other frequency bins or the energy over multiple frequency bins may be summed and compared. For example, frequencies around the fundamental frequency (e.g. bandwidth) may be a better representation of the power. EQUATIONS 1A and 1B show two different cases for calculating a ratio K, of the energy as represented by the power at two different frequencies or in different frequency ranges.
As with many signal processing schemes, signal conditioning may be required to detect and properly represent the energy of the echo signals at the various frequencies. For example, the sensitivity of the detection transducer or attenuation as a function of frequency and depth may need to be introduced to fully appreciate differences in the energy at the various frequencies in tissue.
As described, it is possible to map the energy ratio as a function of frequency and spatial location for an echo. If the excitation level at the transducer is modified, then it is also possible to compare K values for different HIFU transducer pressures. The echoes are also available at different sampling intervals (pulse repetition interval). For example, if a pulse mode HIFU excitation is used, then the echo may be detected and analyzed between the excitation signals. This allows the K values to be compared for multiple excitation levels and/or multiple times.
Ktotal(r0,t0)=Kf
The values of K can be used to select a treatment parameter for the HIFU signals to be used in treating a tissue site by analyzing the K curve determined for the tissue. As indicated above, the system transmits one or more test signals into the patient and detects signals created by the test signals. The ratio, K, of the energy detected in different frequency bands versus depth can be used to create a K curve. The K curve of the detected signals can be compared against known K curves for which treatment parameters have already been determined. For example, breast tissue may be associated with a K curve having a first set of one or more treatment parameters. Fibroid tissue may be associated with another K curve having different treatment parameters. In one embodiment, a processor compares the K curve for the detected signals with a library of K curves to determine the closest match and selects the treatment parameters associated for the closest match.
In another embodiment, one or more individual points on a K curve for the detected signals can be compared with a predetermined baseline K curve. The value for the treatment parameter can be adjusted based on the comparison. For example, if the characteristic curve formed by K as a function of spatial location for the detected signals shows significantly higher ratios than the baseline curve, then the output energy (pressure) may be reduced. Similarly, if the characteristic curve formed by K as a function of spatial location for the detected signals shows significantly lower ratios (or flatter) than the baseline curve, then the output energy may be increased.
It is also possible to show harmonic saturation (maximum value for the ratio K) by graphing the K values as a function of the excitation amplitude for a particular depth. In this case, a number of test HIFU signals are transmitted at different power levels and the K values for the detected signals are computed. A curve or plot of the change in K versus changes in HIFU power for a particular depth are computed. The curve or plot can then be compared against known plots having treatment parameters associated with them. Alternatively, the K curve can be compared with a baseline K curve and the treatment parameters selected.
In one embodiment, one or more points on the K curve for the detected signals are used to select the treatment parameters. In one embodiment, the K curve can be searched for a HIFU power level that causes the value of K to saturate. The treatment parameters of the HIFU signals used to treat a tissue sample can therefore be selected based on the HIFU power which causes the K value to saturate. For example, if the HIFU power that causes the value of K to saturate is 1500 watts, then the treatment parameters associated with a 1500 watt level can be used to treat the tissue. In some cases it may be useful to use the same power to treat the tissue as the power that causes the value of K to saturate. In other cases, other power levels (greater or lessor) could be used.
In yet another embodiment, other characteristics of the K curve for the detected signals can be used to select the treatment parameters. For example, the slope of the K curve can be compared with slopes of K curves having treatment parameters associated with them or the slope of the K curve for the detected signals can be compared with a baseline and the treatment parameters adjusted accordingly.
If the excitation level is constant during the treatment, the energy level of the harmonics and their location may suggest the amount of heating occurring throughout the tissue. This would help determine a limit to the amount of energy delivered to the intended target.
It should be also noted that although the power spectrum has been calculated at different depth and acquisition times, the phase may also be used to determine the amount of heating in tissue.
Since the K-value may be derived by the taking the Fourier transform of the echo signals, the power (energy per unit time) falling within each frequency bin as well as the phase is available for computation. The magnitude and phase in a particular frequency bin may be expressed in the following equation:
H(f1)=A(f1)*e−j2πφ(f
where A(f1) is the amplitude of the signal at frequency f1 (the power is simply the square of A) and φ(f1) is the phase of the signal at frequency f1. Therefore, the phase difference between two frequency bins may be computed by taking the ratio of Equation 3 with the magnitude normalized to 1:
Equation 4 may be rewritten as
εf
The argument in Equation 5 is the phase difference between the two signals. The phase difference as a function of depth at different excitation levels may also be used as a relative measure of energy in different frequencies or frequency bands, which in turn may be used to dynamically control or select a treatment parameter of a HIFU signal. For example, the magnitude of the phrase difference can be compared to a threshold previously known to relate the phase difference to delivered energy in the tissue. One or more characteristics of the HIFU signal can then be adjusted in accordance with the comparison.
Graph 4 shows that the K values may be graphed as a function of position. The ratio K may vary with the depth in the tissue as well as with different levels of transmit excitations. In one embodiment, the ratio K is expected to be a non-linear curve that increases with increasing depth in the tissue, but tends to reach a maximum (or saturate) at approximately the depth of the focal point of the HIFU signal. If K values are calculated after each transmit pulse (graph 5), then multiple K value curves may be generated as shown in graph 4.
Graph 5 shows that the frequency of the transmit pulses may occur at the pulse repetition interval.
Returning to
The energy of the HIFU signal can be modified by increasing or decreasing any of the burst length, the burst interval, the pulse length, the pulse rate interval, or other characteristics such as the pulse amplitude. In one embodiment, the HIFU treatment system automatically varies the acoustic output energy or power as a function of both the characteristic K curve relative to the baseline characteristic curve and whether the device is within an acceptable range for the values of K. An acceptable range for K may have an upper limit for pre-focal and focal values of K, based on safety levels. Other treatment parameters such as treatment time or pulse repetition frequency of the HIFU signals can be selected in a similar manner.
The echo signals are received by the transducer probe 116, converted into an electronic form and supplied to the HIFU controller 110. The detection of the echo signals may take place in the HIFU transducer or another specially designed device contained within the transducer probe 116. Furthermore, the detection device may be in a separate holder not contained within the transducer probe 116.
As previously described, the K values from the echo signals are calculated (
To estimate how much of the incident HIFU energy is being absorbed by the tissue at various positions at or adjacent to the focal point of the HIFU signal, the value of the ratio K is determined from the echo signals received from a given point in the tissue. In one embodiment, the ratio is compared to a desired value of K that was determined from prior testing. The value of the ratio K for the detected signals can therefore be used as a feedback signal to adjust one or more characteristics of the HIFU signal to affect absorption and hence HIFU effects on tissue at a given point. Detection of saturation (acoustic shock waves) or the slope of the increase in the K value as a function of the transmit excitation may also be used as feedback mechanisms to adjust one or more characteristics of the HIFU signal rather than depending on prior testing.
In one embodiment, if the determined value of K for detected signals is below a threshold value for a particular position in the patient, then a signal characteristic such as the amplitude, peak or average power, duty cycle, pulse repetition rate, or other characteristic of the delivered HIFU signals can be electronically or manually increased to increase the ratio K at that position. Conversely, if the determined value of K is above a threshold, then one or more of the amplitude, power, duty cycle, pulse repetition rate, or other characteristic of the HIFU signal can be decreased to decrease the value of K. Different threshold values of K may be used to analyze echo signals received from within the target volume and outside that target volume in the body.
In the example shown in
The feedback mechanism shown in
In yet another embodiment, the system includes an integrated or separate ultrasound imaging system that produces ultrasound images such as B-mode images of the tissue. The value of the ratio K is determined for various points in the body and is color coded or otherwise made visually distinct. The visually distinguished K values in the tissue can then be combined with a B-mode or other type of ultrasound image. In one embodiment, the color coded K values 134 are overlaid onto a B-mode image on the display 132 as shown in
In another embodiment, the system may calculate the center of mass, also called a centroid, for use in the physician's on-screen display, by analyzing the harmonics received by the system. This reduces the overall clutter in the on-screen display.
In another embodiment, the system records the value of the inputs that provide the K ratio value. This allows the system to detect a correlation between pulses in order to build a successive picture of trends in feedback characteristics. This may, for example, provide information valuable in determining whether cavitation or other tissue characteristics have occurred. The system may also make use of pulse inversion in order to create a data set of K ratio values over time for use in feedback analysis that eliminates the fundamental.
Another possible embodiment of this technique is to use baseband detection along with low pass filtering to determine the energy in a detected signal at the fundamental as well as at one or more of the harmonics. The acquired rf vector at a particular power setting is detected and multiplied by sine and cosine waves at the fundamental or harmonic frequencies to obtain baseband data:
Bn(t)=x(t)*exp(−j2πnft)
where f is either the fundamental frequency, n the order of the harmonic (e.g. n is one for the fundamental and 2 for the second harmonic), t is the time vector, x(t) is the original rf waveform, and B, is the baseband detected signal.
After mixing with the sine and cosine waves, the signal is low pass filtered to eliminate energy from other harmonics. The bandwidth of the low pass filter is driven by the bandwidth of the original excitation. After the low pass filter, the signal may be decimated to a lower sampling frequency. The baseband detected signal is associated with a specific transmit power and is a function of depth.
In addition or as an alterative to controlling treatment parameters based on the ratio of the energy in different frequency regions, other characteristics of the detected signals can also be used to select or control the treatment parameters.
As will be described below, the response of a signal characteristic to changes in the power of a transmitted HIFU signal is used to select one or more treatment parameters of HIFU signals that will be used to treat a tissue site.
In the example shown, the response curve shown in
In one embodiment, to select the one or more treatment parameters to be used in treating a tissue site, the response curve for the tissue is determined using a number of test signals transmitted at different power levels. The response curve may be compared to previously known response curves having treatment parameters associated with them. The treatment parameters associated with the previously known response curve that best matches the response curve for the tissue site in question can be used to treat the tissue site. Alternatively, one or more points on the response curve for the tissue can by analyzed to select the one or more treatment parameters.
In one embodiment, the response curves can be analyzed to determine a saturation point, slope or other characteristic such as the shape of the curve.
To automate the determination of the saturation levels in the focal region the response curve is analyzed with a suitably programmed processor or computer. In one embodiment, the goal is to identify the power which exhibits the highest level of scattered energy and thus energy absorption. Ideally regions with significant amounts of harmonic energy would be used to maximize signal-to-noise ratio. For example, the peaks throughout the search region may be selected rather than each sample.
In one embodiment, a look-up-table (LUT) of expected response curves is used to determine the saturation values around the focus. This LUT may consist of response curves predicted theoretically with different characteristics such as attenuation and isentropic non-linearity parameter B/A. Statistical techniques such as correlation are used to compare the theoretical curves to the detected response curve. In this case, it is possible to obtain the saturation power as well as the effective characteristics of the tissue path such as attenuation that can be used to determine the length of treatment time to treat the tissue site.
In another embodiment, the processor or computer is programmed to determine the first and second derivatives of the determined response curve. Next, regions that are concave down with both positive and negative slopes on either side are identified and considered the saturation value.
In yet another embodiment, the expected first and second derivatives are used to code the waveform at a particular depth. Rather than look for a place that has a slope of zero and is concave down, the processor or computer is programmed to use other characteristics of the expected curve predicted by theory or other controlled experiments to increase the confidence that the correct saturation value was chosen. A code is assigned to the expected waveform and the code of the experimental data is determined based on the sign of the first and second derivative. For example, a code of zero is assigned to a slope of zero, a code of one to a negative slope and code of two to a positive slope. In this case, each point analyzed on the response curve could have one of nine possible codes (e.g. 00, 01, 02, 10, 11 etc.). The code is modified only if there is a change between the value of the first and second derivatives between samples, which further compresses the data. A correlation value may be determined between the coded expected value and the coded experimental value to increase the reliability of the algorithm. If the correlation is not above a certain value, then the saturation cannot be determined.
In some embodiments, the curve with the lowest saturation value is used as the prediction. Another method is to average the results through the search region and utilize this for treatment. Ideally, the process for determining the saturation value occurs in real-time such that exorbitant power values are not used.
This idea may be extended to lesions at different depths. In this case, interrogations at different lesion locations are completed. The estimated saturation levels are compared. This allows for the possible calculation of the effective attenuation in the treatment region.
In yet another alternative embodiment of the disclosed technology, the response curve for the detected signals that is analyzed to determine the treatment parameters is related to the temperature change at the focal zone. In this case, HIFU test signals are transmitted and a change in temperature is determined based a detected speckle shift of a reflected signal (echo) or transmitted signal. Speckle shifts are determined for a number of HIFU signals transmitted at different power levels in order to generate the response curve. Preferably the test HIFU signals are sufficiently short so that the tissue in the focal zone does not undergo sustained heating prior to treatment or between test signals. The response curve is analyzed by comparing against predetermined response curves or by determining some characteristic such as its saturation point, whereby the speckle shift no longer increases or decreases with increases in delivered HIFU signal power. Once the response curve has been analyzed either by comparison to previously determined response curves or by analyzing selected points on the response curve, the treatment parameters can be selected.
In yet another alternative embodiment, a response curve related to the dispersion of the waveform transmitted into the tissue is used to control or select the treatment parameter for the HIFU signals to be used to treat the target tissue site.
Dispersion occurs in acoustic waves and is noted by a slight velocity difference of the wavefront that is a function of frequency although the group velocity may remain constant. In high intensity acoustics, dispersion in the wave pulse naturally occurs in regions of high compression due to the production of harmonics. The high pressure and non-linearities of tissue eventually lead to acoustic shock at the highest compressional pressures. The production of harmonics and dispersion are less likely to occur in low pressure pulses. As the pressure is increased, the amount of dispersion increases since harmonics are more easily generated. This dispersion is detected as a phase shift in the waveform as the amplitude of the excitation moves from low pressure to high pressure. The dispersion is seen as movement of the rf signal toward the transducer and is localized by the area of high pressure. This is unique when compared to other effects such as acoustic radiation force (ARF) and apparent phase shifts due to temperature changes. In both of these cases, the expectation is the phase shift is away from the transducer. Furthermore, velocity changes due to temperature are an integrative effect in tissue. In other words, where the local temperature has increased, the shift will appear at that point as well as for every point behind the thermal increase.
The resulting phase shifts shown in
Dispersion may be detected as a slight shift in the image or speckle toward the HIFU transducer as test signals of successively higher power are applied to the tissue. This is illustrated in
As the power level is increased, there is a corresponding increase in production of harmonics at the focal region—which in turn reduces the time to receive the signal scattered from the focal region, due to dispersion. This reduced time can be perceived as a spatial shift in the ultrasound image towards the transducer, assuming the signals are displayed graphically.
As shown in the attached flowchart of
After delivering the test signals with the different power level settings, the speckle shift associated with adjacent power level settings is determined. A response curve showing the change in the speckle shift versus changes in HIFU power is created with a programmed processor or computer. The response curve is analyzed and used to select one or more treatment parameters. For example, a programmed processor can analyze the response curve to determine a power level at which the speckle shift saturates i.e. doesn't change with further increases in power or the amount of speckle shift decreases with further increased power. In one embodiment, the treatment parameters are selected based on the power level of the HIFU that causes saturation. Other signals characteristics such as the slope of the response curve can be used to select the treatment parameters. In yet another alternative embodiment, the response curve can be compared with predefined response curves having treatment parameters associated with them. The treatment parameters associated with the response curve that best matches the determined response curve can be used to treat the tissue.
In one embodiment, treatment of each location within an intended treatment volume may be immediately preceded by determination of the treatment parameters for that location. In another embodiment, the treatment parameters may be determined at a variety of locations within an intended treatment volume prior to commencing treatment of any such location. The treatment parameters for each location are then stored in a memory or other computer readable media. Once treatment begins, the selected treatment parameters are recalled for each such location and used to treat that location. In yet another embodiment, the treatment parameters selected for one location can be used to treat an entire volume of tissue.
To maximize the accuracy and consistency of this method for selecting treatment parameters, the successive test HIFU signals should be spaced together closely in time so as to minimize any spatial shifts that might occur due to tissue motion (e.g. due to breathing or other patient motion).
In addition, the test signals should be applied in a manner which minimizes local heating of tissue, so as to avoid shifts that might occur due to changes in local sound velocity.
In yet another embodiment, the energy in a received signal at harmonics of the fundamental frequency of the HIFU signal can be estimated by measuring the energy at the fundamental frequency. This technique allows a more narrow band detection system to be used.
If a HIFU signal is delivered to the tissue at power P1 (that is selected to be low enough not to create energy at the harmonics in the tissue) and at a distance r, the HIFU signal will produces a signal with energy at the fundamental frequency of the HIFU signal that is defined by a function:
Xf(P1,r) (6)
If the tissue behaved linearly, then the energy at the fundamental of a signal created from a HIFU signal that is transmitted at a higher power level P2, should be related to the different power level by the function:
However the tissue generally does not respond linearly to higher power levels of HIFU signals. Therefore the measured energy at the fundamental frequency of a signal that is created in response to a higher power HIFU signal will differ from the prediction. The difference is related to the energy that is being converted into the energy at the harmonics.
To estimate the energy at the harmonics, the energy of a received signal at the fundamental frequency of the HIFU signal that is delivered at a power level P2 is determined. The difference between the energy measured and the energy predicted is calculated. according to the function:
where Xh is the energy at the harmonics. The ratio of the energy in the harmonics to the energy at the fundamental frequency of the HIFU signals is therefore given by the function:
A response curve can therefore be created that relates the energy of the harmonics to increases in the energy of the HIFU signals delivered. The response curve can be analyzed by a programmed processor or computer and used to select the treatment parameters either by comparison against predetermined response curves having treatment parameters associated therewith or by analyzing characteristics of the response curve and selecting treatment parameters associated with the characteristics.
In yet another embodiment, the “focal gain” i.e. the increased energy absorption caused by the energy level of the harmonics that is created in the tissue can be estimated by comparing the energy of the signals created from HIFU signals at different powers. If the tissue were linear, then the following relationship should hold for different HIFU power levels.
However as the power level increases, more energy is transferred to the harmonics and the ratio should become less than one with a drop in the detected energy at the HIFU power level that causes a saturation if measured with a narrow band receiver or a gain in the detected energy at the energy level that causes saturation if measured with a wide band receiver. Therefore, a response curve can be determined that relates the ratio of detected energy to predicted energy at several different HIFU power levels. The response curve can then be analyzed or compared to other response curves in order to select one or more treatment parameters.
As will be appreciated by those skilled in the art, the deposition of energy at a treatment site is effected by the tissue's “alpha” value that is related to attenuation as well as its “B/A” value that is related to the tissue's isentropic non-linearity parameter B/A.
The alpha value for the tissue treatment site can be estimated by measuring the energy of a signal created in response to a test HIFU signal at a fixed power. The transducer can then be moved away from the treatment site and the space filled with a medium of known attenuation e.g. water. A second test HIFU signal is then applied to the tissue and the energy detected. A response curve in this example therefore relates the difference in energies detected and the distance that the transducer was moved. From the estimated attenuation of the tissue, a treatment regimen (power and treatment duration or other treatment parameter) can be selected based on predetermined clinical data performed on tissue types with similar alpha values. The alpha value for the tissue can be determined by comparing response curves for different spatial locations in the tissue.
The B/A value for a tissue site to be treated can be estimated based on comparison of the tissue's response curve with response curves computed for tissue types with known B/A values.
As indicated above, the treatment parameters such as power level, pulse duration, pulse repetition frequency etc. are selected based on an analysis of the response of the tissue to be treated to a HIFU pulse. The particular values for these treatment parameters will be based on clinical data and stored in a manner that can be indexed based on an analysis of the response curve for the treatment site. The parameter data is typically stored in a computer readable media, hard drive, CD ROM, solid state memory etc, that is accessed by a local or remote computer. When needed, the recalled treatment parameters are applied to the HIFU control hardware so that the tissue can be treated.
In addition or as an alternative to selecting or adjusting the energy of the delivered HIFU signals, the disclosed technology can be used to redirect the focus point of the delivered signals. In the embodiment shown in
If the response curves are created based on other signal characteristics, the focus can be redirected based on the response curves determined for each of the spatial locations.
Although illustrative embodiments of the disclosed technology have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the scope of the technology. For example, the response curves may also be produced for a change in acoustic radiation force (ARF) that relates movement of the tissue to changes in power of the test signals. In addition, the disclosed technology is not limited to the delivery of HIFU signals to the patient but can be applied to the delivery of any waveform such as non-focused ultrasound to a non-linear medium such as tissue. Therefore, the scope of the technology is to be determined solely by the following claims and equivalents thereof.
Darlington, Gregory P., Reed, Justin A., Emery, Charles D., Friemel, Barry
Patent | Priority | Assignee | Title |
11707629, | May 28 2009 | AngioDynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
11723710, | Nov 17 2016 | AngioDynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
11752365, | Feb 09 2016 | THEUER, IRMENGARD; THEUER, AXEL ERICH; THEUER, AXEL ERICH, DR | Device for treating malignant diseases with the help of tumor-destructive mechanical pulses (TMI) |
11779395, | Sep 28 2011 | AngioDynamics, Inc. | Multiple treatment zone ablation probe |
9757196, | Sep 28 2012 | AngioDynamics, Inc. | Multiple treatment zone ablation probe |
Patent | Priority | Assignee | Title |
3470868, | |||
3480002, | |||
3676584, | |||
3941112, | Jun 22 1973 | Ducellier et Cie | Ignition device for internal combustion engines |
4059098, | Jul 21 1975 | Stanford Research Institute | Flexible ultrasound coupling system |
4097835, | Sep 20 1976 | SRI International | Dual transducer arrangement for ultrasonic imaging system |
4185502, | Oct 11 1977 | Transducer coupling apparatus | |
4282755, | Dec 05 1979 | Technicare Corporation | Transducer drive and control |
4347850, | Mar 19 1980 | ADVANCED RESEARCH, INC , A CORP OF IN | Direct water coupling device for ultrasound breast scanning in a supine position |
4484569, | Mar 13 1981 | CORNELL RESEARCH FOUNDATION, INC EAST HILL PLAZA, ITHACA, N Y 14850 | Ultrasonic diagnostic and therapeutic transducer assembly and method for using |
4742829, | Aug 11 1986 | GENERAL ELECTRIC COMPANY, MILWAUKEE, WI A CORP OF NY | Intracavitary ultrasound and biopsy probe for transvaginal imaging |
4756313, | Nov 05 1986 | DIASONICS, INC | Ultrasonic probe |
4819621, | Mar 11 1986 | RICHARD WOLF GMBH, KNITTLINGEN, GERMANY | Method for detection of cavitations during medical application of high sonic energy |
4835689, | Sep 21 1987 | General Electric Company | Adaptive coherent energy beam formation using phase conjugation |
4858613, | Mar 02 1988 | LABORATORY EQUIPMENT, CORP , A CORP OF INDIANA | Localization and therapy system for treatment of spatially oriented focal disease |
4865042, | Aug 16 1985 | Hitachi, Ltd. | Ultrasonic irradiation system |
4893624, | Jun 21 1988 | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, 77 MASSACHUSETTS AVENUE, CAMBRIDGE, MASSACHUSETTS A CORP OF MA | Diffuse focus ultrasound hyperthermia system |
4932414, | Nov 02 1987 | Cornell Research Foundation, Inc.; Riverside Research Institute | System of therapeutic ultrasound and real-time ultrasonic scanning |
5005579, | Feb 17 1987 | Richard Wolf GmbH | Apparatus for spatial location and destruction of objects inside the body by means of ultrasound |
5036855, | Mar 02 1988 | Laboratory Equipment, Corp. | Localization and therapy system for treatment of spatially oriented focal disease |
5070879, | Nov 30 1989 | U-Systems, Inc | Ultrasound imaging method and apparatus |
5080101, | Dec 14 1983 | TECHNOMED MEDICAL SYSTEMS, S A | Method for examining and aiming treatment with untrasound |
5080102, | Dec 14 1983 | TECHNOMED MEDICAL SYSTEMS, S A | Examining, localizing and treatment with ultrasound |
5080660, | May 11 1990 | Applied Medical Resources Corporation | Electrosurgical electrode |
5117832, | Sep 21 1990 | THS INTERNATIONAL, INC | Curved rectangular/elliptical transducer |
5234429, | Jul 06 1992 | Cauterization instrument and associated surgical method | |
5271402, | Jun 02 1992 | Agilent Technologies Inc | Turbine drive mechanism for steering ultrasound signals |
5391140, | Jan 29 1993 | Siemens Aktiengesellschaft | Therapy apparatus for locating and treating a zone in the body of a life form with acoustic waves |
5441499, | Jul 14 1993 | Dekna elektro-u. medizinische Apparatebau Gesellschaft mbH | Bipolar radio-frequency surgical instrument |
5471988, | Dec 24 1993 | Olympus Optical Co., Ltd. | Ultrasonic diagnosis and therapy system in which focusing point of therapeutic ultrasonic wave is locked at predetermined position within observation ultrasonic scanning range |
5474071, | Mar 05 1991 | Technomed Medical Systems | Therapeutic endo-rectal probe and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe |
5492126, | May 02 1994 | THS INTERNATIONAL, INC | Probe for medical imaging and therapy using ultrasound |
5520188, | Nov 02 1994 | THS INTERNATIONAL, INC | Annular array transducer |
5558092, | Jun 06 1995 | CEREVAST THERAPEUTICS, INC | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
5619999, | Dec 28 1995 | Siemens Medical Solutions USA, Inc | Body surface position locator for ultrasound transducer |
5666954, | Mar 05 1991 | Technomed Medical Systems | Therapeutic endo-rectal probe, and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe |
5720287, | Jul 26 1993 | Technomed Medical Systems | Therapy and imaging probe and therapeutic treatment apparatus utilizing it |
5762066, | Feb 21 1992 | THS INTERNATIONAL, INC ; THS INTERNATIONAL, INC , A DELAWARE CORPORATION | Multifaceted ultrasound transducer probe system and methods for its use |
5769790, | Oct 25 1996 | Insightec Ltd | Focused ultrasound surgery system guided by ultrasound imaging |
5810007, | Jul 26 1995 | HARVARD MEDICAL SCHOOL | Ultrasound localization and image fusion for the treatment of prostate cancer |
5882302, | Feb 21 1992 | THS INTERNATIONAL, INC | Methods and devices for providing acoustic hemostasis |
5976092, | Jun 15 1998 | Combination stereotactic surgical guide and ultrasonic probe | |
5984881, | Mar 31 1995 | Kabushiki Kaisha Toshiba | Ultrasound therapeutic apparatus using a therapeutic ultrasonic wave source and an ultrasonic probe |
5993389, | May 22 1995 | FOCUS SURGERY | Devices for providing acoustic hemostasis |
6002251, | Dec 15 1995 | Electromagnetic-field-focusing remote-field eddy-current probe system and method for inspecting anomalies in conducting plates | |
6007499, | Oct 31 1997 | SONIC CONCEPTS, INC | Method and apparatus for medical procedures using high-intensity focused ultrasound |
6042556, | Sep 04 1998 | University of Washington | Method for determining phase advancement of transducer elements in high intensity focused ultrasound |
6050943, | Oct 14 1997 | GUIDED THERAPY SYSTEMS, L L C | Imaging, therapy, and temperature monitoring ultrasonic system |
6071239, | Oct 27 1997 | Method and apparatus for lipolytic therapy using ultrasound energy | |
6083159, | May 22 1995 | THS International, Inc. | Methods and devices for providing acoustic hemostasis |
6126607, | Nov 03 1997 | CIVCO MEDICAL INSTRUMENTS CO , INC | Ultrasound interface control system |
6196972, | Nov 11 1998 | SPENTECH, INC | Doppler ultrasound method and apparatus for monitoring blood flow |
6217530, | May 14 1999 | University of Washington | Ultrasonic applicator for medical applications |
6254601, | Dec 08 1998 | Vascular Control Systems, Inc | Methods for occlusion of the uterine arteries |
6267734, | Mar 31 1995 | Kabushiki Kaisha Toshiba | Ultrasound therapeutic apparatus |
6315741, | Oct 31 1997 | SONIC CONCEPTS, INC | Method and apparatus for medical procedures using high-intensity focused ultrasound |
6390973, | Jun 25 1998 | Hoya Corporation | Endoscope for ultrasonic examination and surgical treatment associated thereto |
6425867, | Sep 18 1998 | MIRABILIS MEDICA, INC | Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy |
6432067, | Oct 31 1997 | SONIC CONCEPTS, INC | Method and apparatus for medical procedures using high-intensity focused ultrasound |
6451013, | Jan 19 2000 | Medtronic Xomed, Inc | Methods of tonsil reduction using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
6461314, | Feb 02 1999 | MISONIX, INC | Intrabody hifu applicator |
6488639, | May 13 1998 | Technomed Medical Systems, S.A; Institut National de la Santa et de la Recherche Medicale | Frequency adjustment in high intensity focused ultrasound treatment apparatus |
6500133, | May 14 1999 | University of Washington | Apparatus and method for producing high intensity focused ultrasonic energy for medical applications |
6508774, | Mar 09 1999 | PROFOUND MEDICAL INC | Hifu applications with feedback control |
6537224, | Jun 08 2001 | Vermon | Multi-purpose ultrasonic slotted array transducer |
6602251, | Dec 08 1998 | Vascular Control Systems, Inc. | Device and methods for occlusion of the uterine artieries |
6613004, | Apr 21 2000 | Insightec Ltd | Systems and methods for creating longer necrosed volumes using a phased array focused ultrasound system |
6626855, | Nov 26 1999 | OTSUKA MEDICAL DEVICES CO , LTD | Controlled high efficiency lesion formation using high intensity ultrasound |
6632177, | May 01 2002 | Siemens Medical Solutions USA, Inc | Dual process ultrasound contrast agent imaging |
6633658, | Mar 17 2000 | Senorx, Inc | System and method for managing intermittent interference on imaging systems |
6645162, | Dec 27 2000 | Insightec Ltd | Systems and methods for ultrasound assisted lipolysis |
6666822, | Apr 04 2001 | FUJIFILM Corporation | Ultrasonic imaging method and apparatus |
6666835, | May 14 1999 | University of Washington | Self-cooled ultrasonic applicator for medical applications |
6676601, | May 26 1999 | Technomed Medical Systems, S.A.; Institut National de la Sante et de la Recherche Medicale (INSERM) | Apparatus and method for location and treatment using ultrasound |
6692450, | Jan 19 2000 | Medtronic Xomed, Inc | Focused ultrasound ablation devices having selectively actuatable ultrasound emitting elements and methods of using the same |
6716184, | Sep 18 1998 | MIRABILIS MEDICA, INC | Ultrasound therapy head configured to couple to an ultrasound imaging probe to facilitate contemporaneous imaging using low intensity ultrasound and treatment using high intensity focused ultrasound |
6719694, | Dec 23 1999 | OTSUKA MEDICAL DEVICES CO , LTD | Ultrasound transducers for imaging and therapy |
6740082, | Dec 29 1998 | Mederi RF, LLC; HORIZON CREDIT II LLC | Surgical instruments for treating gastro-esophageal reflux |
6764488, | Dec 08 1998 | Vascular Control Systems, Inc. | Devices and methods for occlusion of the uterine arteries |
6837855, | Dec 18 1997 | Use of an ultrasonic transducer for echographic exploration of human or animal body tissues or organs in particular of the eyeball posterior segment | |
6840936, | Oct 22 1996 | EPICOR, INC | Methods and devices for ablation |
6936046, | Jan 19 2000 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
7061381, | Apr 05 2002 | BeezerBug Incorporated | Ultrasonic transmitter and receiver systems and products using the same |
7063666, | Dec 23 1999 | OTSUKA MEDICAL DEVICES CO , LTD | Ultrasound transducers for imaging and therapy |
7105007, | Nov 21 2002 | Cervical medical device, system and method | |
7175596, | Oct 29 2001 | Insightec Ltd | System and method for sensing and locating disturbances in an energy path of a focused ultrasound system |
7258674, | Feb 20 2002 | Medicis Technologies Corporation | Ultrasonic treatment and imaging of adipose tissue |
7286499, | Jul 10 1998 | Qualcomm Incorporated | Methods and apparatuses for fast power control of signals transmitted on a multiple access channel |
7452357, | Oct 22 2004 | Cilag GmbH International | System and method for planning treatment of tissue |
7470241, | Nov 26 1999 | OTSUKA MEDICAL DEVICES CO , LTD | Controlled high efficiency lesion formation using high intensity ultrasound |
7473224, | May 29 2001 | Ethicon Endo-Surgery, Inc | Deployable ultrasound medical transducers |
7674630, | Sep 24 2004 | Spectronic AB | Method and device for separating particles |
7699782, | Mar 09 2004 | Extended, ultrasound real time 3D image probe for insertion into the body | |
7993289, | Dec 30 2003 | Medicis Technologies Corporation | Systems and methods for the destruction of adipose tissue |
8016757, | Sep 30 2005 | University of Washington | Non-invasive temperature estimation technique for HIFU therapy monitoring using backscattered ultrasound |
20010012934, | |||
20010017848, | |||
20020029036, | |||
20020065512, | |||
20020120192, | |||
20020120259, | |||
20020147397, | |||
20030004439, | |||
20030060736, | |||
20030149380, | |||
20030189488, | |||
20030233045, | |||
20040030268, | |||
20040030269, | |||
20040039312, | |||
20040082859, | |||
20040153126, | |||
20040242999, | |||
20040243201, | |||
20050038340, | |||
20050085726, | |||
20050101854, | |||
20050107702, | |||
20050154431, | |||
20050203399, | |||
20050256405, | |||
20050267454, | |||
20050281444, | |||
20060052701, | |||
20060056273, | |||
20060264748, | |||
20070010805, | |||
20070016042, | |||
20070066990, | |||
20070083120, | |||
20070106157, | |||
20070167798, | |||
20070194658, | |||
20070197918, | |||
20070238994, | |||
20070239011, | |||
20070255267, | |||
20070270792, | |||
20080039724, | |||
20080058683, | |||
20080071165, | |||
20080086036, | |||
20080125771, | |||
20080154131, | |||
20080217259, | |||
20080221647, | |||
20080253525, | |||
20080281314, | |||
20080319436, | |||
20090000626, | |||
20090036774, | |||
20090069677, | |||
20090228001, | |||
20090326420, | |||
EP301360, | |||
EP614651, | |||
EP734742, | |||
EP1726267, | |||
GB2279742, | |||
JP11313833, | |||
JP2001253836, | |||
JP2001526076, | |||
JP2006204929, | |||
JP2007144183, | |||
JP405023336, | |||
JP58173539, | |||
WO45706, | |||
WO171380, | |||
WO182777, | |||
WO2100486, | |||
WO2004073524, | |||
WO2005000097, | |||
WO2006097661, | |||
WO2006129099, | |||
WO9317646, | |||
WO9427502, | |||
WO9520360, | |||
WO9700646, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Aug 06 2009 | Mirabilis Medica Inc. | (assignment on the face of the patent) | / | |||
Aug 06 2009 | DARLINGTON, GREGORY P | MIRABILIS MEDICA INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023091 | /0261 | |
Aug 06 2009 | EMERY, CHARLES D | MIRABILIS MEDICA INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023091 | /0261 | |
Aug 06 2009 | REED, JUSTIN A | MIRABILIS MEDICA INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023091 | /0261 | |
Aug 06 2009 | FRIEMEL, BARRY | MIRABILIS MEDICA INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023091 | /0261 |
Date | Maintenance Fee Events |
Sep 23 2019 | REM: Maintenance Fee Reminder Mailed. |
Jan 28 2020 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
Jan 28 2020 | M2554: Surcharge for late Payment, Small Entity. |
Sep 25 2023 | REM: Maintenance Fee Reminder Mailed. |
Mar 11 2024 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Feb 02 2019 | 4 years fee payment window open |
Aug 02 2019 | 6 months grace period start (w surcharge) |
Feb 02 2020 | patent expiry (for year 4) |
Feb 02 2022 | 2 years to revive unintentionally abandoned end. (for year 4) |
Feb 02 2023 | 8 years fee payment window open |
Aug 02 2023 | 6 months grace period start (w surcharge) |
Feb 02 2024 | patent expiry (for year 8) |
Feb 02 2026 | 2 years to revive unintentionally abandoned end. (for year 8) |
Feb 02 2027 | 12 years fee payment window open |
Aug 02 2027 | 6 months grace period start (w surcharge) |
Feb 02 2028 | patent expiry (for year 12) |
Feb 02 2030 | 2 years to revive unintentionally abandoned end. (for year 12) |